Potent cytotoxicity against human small cell lung cancer cells of the heptenes from the stem bark of Xylopia pierrei Hance

Phytochemical investigation of the stem bark of Xylopia pierrei Hance led to the isolation of one triterpene, polycarpol ( 1 ), three heptenes, (7 R )-acetylmelodorinol ( 2 ), (7 R )-melodorinol ( 3 ), and melodienone ( 8 ), and four flavonoids, pinocembrin ( 4 ), isochamanetin ( 5 ), chrysin ( 6 ),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicinal chemistry research 2017-06, Vol.26 (6), p.1291-1296
Hauptverfasser: Chokchaisiri, Ratchanaporn, Kunkaewom, Sukanya, Chokchaisiri, Suwadee, Ganranoo, Lucksagoon, Chalermglin, Rattana, Suksamrarn, Apichart
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Phytochemical investigation of the stem bark of Xylopia pierrei Hance led to the isolation of one triterpene, polycarpol ( 1 ), three heptenes, (7 R )-acetylmelodorinol ( 2 ), (7 R )-melodorinol ( 3 ), and melodienone ( 8 ), and four flavonoids, pinocembrin ( 4 ), isochamanetin ( 5 ), chrysin ( 6 ), and dichamanetin ( 7 ). All compounds were isolated for the first time from this plant species. The structures of the isolated compounds were characterized by spectroscopic techniques and by comparison of the spectroscopic data with the literature values and the stereochemistry at the asymmetric carbon was determined by the modified Mosher’s method. Among them, compound 2 displayed potent cytotoxic activity against human small cell lung cancer (NCI-H187) cells with an IC 50 value of 6.66 μM and it was 2.3-fold higher than that of the reference anticancer drug, ellipticine. In addition, compound 2 was also evaluated against the non-cancerous Vero cells and showed high selectivity index of 8.89, which is 59-fold greater than that of ellipticine. The findings suggest that compound 2 should be further developed as a potential lead molecule for anticancer drug development.
ISSN:1054-2523
1554-8120
DOI:10.1007/s00044-017-1843-8